While many of the points raised recently are quite valid, the sudden worrying about the price of the stock and the urgent need for funding seems to me like a lot of noise and bluster from people who have short attention spans.
Take a look at the chart of this stock over the last 3 years - or of the entire life of the company; it looks more or less exactly like a "developmental" company - a typical penny stock. In just the last 6 or 7 months the price has finally begun to climb out of the primordial soup, due to the announcements of the scientific breakthroughs, and the company is now poised to make the transistion from a developmental company into a real business. Sure - it would be nice to hear from the CEO every 2 weeks about the talks they have with venture capitlaists, or with banks or even with pharmaceutical companies, but that's not the way business is done. (Frankly, it would be awful if it WAS done that way.) They don't name names and announce deals until the papers are signed.
At the shareholder's meeting I imagine that people will be asking them if they are in negotiation with other parties - for funding, licensing, what have you, but the answer will be non-commital, and while they may say they are currently talking to a number of parties with regard to these matters, they simply won't name names.
I'd like to suggest that we could come up with a shortlist of valid questions that an attending member or members here could ask on our behalf. To me the CFO guy seems a bit suspect, now that his credentials have been brought up.
